Posted by Michael Wonder on 11 Feb 2025
Heart drug Beyonttra (acoramidis) approved in EU for treatment of transthyretin amyloidosis in adults with cardiomyopathy
11 February 2025 - Approval based on positive results from Phase 3 ATTRibute-CM study.
The European Commission has granted marketing authorisation in the European Union for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
